Stretch Marks on Abdomen

NCT ID: NCT03750422

Last Updated: 2019-05-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-01
• Study Completion Date: 2019-12-31

Brief Summary

The primary objective of this study is to determine the effect of Stratacel® wound dressing on cosmetic outcomes following 1064/532nm picosecond laser (Picoway®, Syneron Candela Corp, Wayland, MA, USA) treatment of abdominal striae alba. Secondary objectives include examining the effect of Stratacel® wound dressing on post-laser healing and symptomatology.

Detailed Description

Twenty adult subjects with abdominal striae alba will be enrolled. All striae will be treated using the 1064/532nm picosecond laser with designated and standardized settings (Appendix A). The abdominal striae treatment region will then be split across the body vertically with one half randomized to Stratacel® and the other to placebo, clear ultrasound gel (Aquasonic). A blinded study coordinator will apply the products to each randomized half-abdomen immediately following laser treatment.

A total of 3 treatments will be completed at 1 month intervals. Blinded-investigator and subject self-assessments will be performed at post-treatment days 2, 5, 7, and 10 after each laser session. Assessments will also be performed 1 and 3 months after the final laser treatment.

Conditions

Striae; Albicantes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Stratacel

medical grade silicone gel following Picoway Laser treatment

Group Type: ACTIVE_COMPARATOR

Picoway

Intervention Type: DEVICE

1064/532nm picosecond laser

Stratacel

Intervention Type: OTHER

a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties

Vehicle

Clear ultrasound gel following Picoway Laser treatment

Group Type: SHAM_COMPARATOR

Picoway

Intervention Type: DEVICE

1064/532nm picosecond laser

Aquasonic

Intervention Type: OTHER

clear ultrasound gel

Interventions

Picoway

1064/532nm picosecond laser

Intervention Type: DEVICE

Stratacel

a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties

Intervention Type: OTHER

Aquasonic

clear ultrasound gel

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Females or Males in good general health >18 years of age.

2. Must be willing to give and sign a photography release, HIPPA and informed consent.

3. Subject must have at least 2 white striae on each treatment side of the abdomen that measure at least 1cm in length.

4. Females will be either of non-childbearing potential defined as:

1. Having no uterus 2. No menses for at least 12 months.

Or:

Women of childbearing potential must agree to use an effective method of birth control during the course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. Expectable forms of birth control below:

1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device

2. Intrauterine coil

3. Bilateral tubal ligation

4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)

5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).

6. Vasectomized (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized partner).

Exclusion Criteria

1. Pregnancy, planned pregnancy during the course of the study or currently breast feeding.

2. Projected significant fluctuations in weight during the course of the study or within the last 6 months, per investigator discretion.

1. Recent use of self-tanners, excessive exposure to sunlight, artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning and/or use of self-tanners during the course of the study.

2. Any planned surgical or cosmetic procedure in the treatment area during the course of the study.

3. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.

4. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.

5. Red or brown colored striae in the intended treatment area.

6. Active dermatitis, open wound, active bacterial, neurologic, fungal, or viral infection in the proposed treatment area.

7. Inability to ambulate following the procedure.

8. History of skin tightening or other treatment in the striae region in the preceding 12 months before study enrollment and for duration of the study.

9. Use of topical retinoids, hydroquinone, medicated cleansers, cellulite creams, or steroids to the treatment area within the preceding 2 weeks and for duration of the study.

10. Allergy to any ingredient in the study medication or placebo.

11. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Goldman, Butterwick, Fitzpatrick and Groff

OTHER

Sponsor Role: lead

Responsible Party

Isabella Guiha

CCRC

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mitchel P Goldman, MD

Role: PRINCIPAL_INVESTIGATOR

Cosmetic Laser Dermatology

Locations

West Dermatology Research Center

San Diego, California, United States

Countries

United States

Other Identifiers

STRATPHARMA-2018-01

Identifier Type: -

Identifier Source: org_study_id